- Clinical Pipeline
- Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
- ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
- Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
- ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
- ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
- Partnered Products and Programs
- Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
- Balversa® (erdafitinib) FGFr inhibitor (Oncology)
- AZD5363 PKB/Akt Inhibitor (Oncology)
- Multiple Targets and Therapeutic Areas
- Pyramid™ Discovery Platform
- Oncology and CNS Discovery
- Sustaining Innovation
Integrated Platform, Innovative Solutions
Astex is recognized as a pioneer and global leader in fragment-based drug discovery, a new way of generating novel small molecule drugs, and one of the most significant advances in drug discovery in the past 20 years.
Advantages of fragment-based drug discovery
- Designed to reduce attrition during drug development
- Carefully monitors key characteristics such as ligand efficiency and in vivo activity during lead optimization
- Ensures delivery of potent, selective and low molecular weight compounds with optimized drug metabolism and pharmacokinetic properties
- Generates higher quality leads by optimizing key drug properties earlier in the process